Cleaved CDCP1 Antibodies for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective antibodies that specifically bind to cleaved CDCP1, a protein associated with increased malignancy and poor prognosis in various cancers, limiting their ability to diagnose and treat cancers with overexpressed cleaved CDCP1.
Innovation Solution
Development of antibodies and antigen-binding fragments that preferentially bind to cleaved CDCP1, specifically targeting the cleaved form without binding to full-length CDCP1, utilizing specific amino acid sequences and post-translational modifications for enhanced specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current therapies use antibodies, then they can treat various cancers, but they cannot specifically bind to cleaved CDCP1 which is associated with increased malignancy and poor prognosis
Solution Approach 1:
The antibody is designed to recognize and bind specifically to the cleaved form of CDCP1 protein, which has a distinct epitope structure compared to the full-length protein. This local specificity allows the antibody to target only the cleaved form that is associated with increased malignancy, enabling precise identification and treatment of aggressive cancer phenotypes without cross-reacting with normal or less aggressive cancer cells expressing full-length CDCP1.
2Measurement precision
If antibodies are developed to target cleaved CDCP1, then diagnosis and treatment of aggressive cancers can be improved, but the ability to differentiate between cleaved and full-length CDCP1 forms presents a challenge
Solution Approach 1:
The antibody design focuses on recognizing specific structural parameters of the cleaved CDCP1 epitope, particularly the conformational changes that occur upon proteolytic cleavage. By targeting these parameter changes in the protein structure rather than attempting to detect all possible variations, the antibody achieves high differentiation capability with a relatively simple single-chain variable fragment design.
3Reliability
If antibodies specifically bind to cleaved CDCP1, then tumor growth and metastasis can be inhibited, but the lack of existing antibodies limits current therapeutic options
Solution Approach 1:
The invention extracts and isolates the specific variable region sequences from the antibody that are responsible for binding to the cleaved CDCP1 epitope. By focusing on this essential functional component (the single-chain variable fragment), the therapy achieves the desired therapeutic effect while simplifying the manufacturing process and reducing production complexity compared to producing full IgG molecules.
Data Source
AI summary
The disclosure provides antibodies that specifically bind to a cleaved CDCP1 and antigen binding fragments thereof and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an antibody or antigen-binding fragment thereof that specifically binds to a cleaved human CDCP1.